The OpenFold Consortium Names Dr. Jan Domanski as Senior Science Lead to Drive the Next Generation of Open Source AI Models for Structural Biology and Drug Discovery
The OpenFold Consortium, a leading open-science initiative developing AI foundation models for biomolecular structure prediction, today announced that Dr. Jan Domanski has joined the consortium as senior science lead. In this role, Dr. Domanski will spearhead scientific innovation, engineering excellence, and ecosystem growth as OpenFold advances its mission to democratize access to high-performance AI models for structural biology and drug discovery. He will work closely with Dr. Jennifer Wei, OpenFold’s senior technical lead, and a global network of academic and industry contributors to build an open, modular software stack that links state-of-the-art AI models with rich experimental and simulation data to improve model generalization and robustness for drug discovery.
OpenFold Consortium Releases Preview of OpenFold3: An Open-Source Foundation Model for Structure Prediction of Proteins, Nucleic Acids, and Drugs
The OpenFold Consortium, a leading nonprofit artificial intelligence (AI) research consortium, today announced a preview release of OpenFold3, an open-source deep learning model that predicts three-dimensional structures of complex proteins and their interacting molecules with high accuracy. Trained on more than 300,000 publicly-available, experimentally determined structures, and an OpenFold-curated synthetic database of over 13 million structures, OpenFold3 provides the underpinning to significantly accelerate in silico screening of biomolecules and serves as a foundation model for next-generation protein AI tools across drug discovery, enzyme and biosensor design, and biomaterials development.
OpenFold Biotech AI Research Consortium releases SoloSeq and Multimer, an integrated protein Large Language Model with 3D structure generation
OpenFold, a non-profit artificial intelligence (AI) research consortium, today announced the release of two new tools: 1) SoloSeq, which integrates a new protein Large Language Model (LLM) with its OpenFold structure prediction software, and 2) OpenFold-Multimer software, which creates higher quality models of protein/protein complexes than OpenFold alone. The new SoloSeq model, built on Amazon Web Services (AWS), is the first fully open source integrated protein LLM/structure prediction AI tool, and the first such model to release a critical training code that other organizations can use for fine tuning or new model training on their own proprietary data. This will enable new science that is not possible with closed-source existing models. The new Multimer code is the first fully open source training code system for the generation of protein/protein structures. This work was led by Prof. Mohammed AlQuraishi at Columbia University with Sachin Kadyan, Kevin Zhu, Christina Floristean, Dingquan Yu, Gustaf Ahdritz and Jennifer Wei.
OpenFold AI Research Consortium Welcomes New Members Including Bristol Myers Squibb, COGNANO, Lambda, Novo Nordisk, Structure Therapeutics, Tamarind, Unnatural Products, and Visterra
OpenFold, a non-profit AI research consortium dedicated to creating free, open-source software tools for biology and drug discovery, announced today eight new industry partners. Joining the consortium are Bristol Myers Squibb, COGNANO, Lambda, Novo Nordisk, Structure Therapeutics, Tamarind Bio, Unnatural Products, and Visterra, each bringing valuable expertise and a shared commitment to harnessing AI technologies to accelerate drug discovery. With these additions, OpenFold continues to expand its collaborative network of academic and industry leaders for the advancement of open-source AI in molecular sciences.
OpenFold AI Research Consortium Welcomes Three New Members: UCB, NVIDIA and Valence Labs
OpenFold, a non-profit artificial intelligence (AI) research consortium whose goal is to develop free and open-source software tools for biology and drug discovery, today announced the addition of three new industry members: UCB, NVIDIA, and Valence Labs (powered by Recursion). UCB and Valence Labs expand OpenFold’s reach and support within the pharmaceutical and TechBio industries, while NVIDIA’s AI computing expertise will help accelerate the technical progress of the consortium.
OpenFold AI Research Consortium Welcomes Six New Members: Astex, Biogen, Congruence, Polaris Quantum, Psivant, and SandboxAQ
OpenFold, a leading non-profit artificial intelligence (AI) research consortium focused on developing free and open source software tools for biology and drug discovery, today announced the addition of six new industry members. Joining the consortium are Astex Pharmaceuticals, Biogen, Congruence Therapeutics, Polaris Quantum Biotech, Psivant Therapeutics, and SandboxAQ, bringing unique expertise and a commitment to leveraging AI technologies to accelerate drug discovery and improve patient outcomes.
